Christopher Sweeney on the Future of Prostate Cancer Care
Christopher Sweeney, MBBS, Medical Oncologist, gives us his insight on the future of prostate cancer care and research in the year 2027.
Related Articles
Predictors of Renal Function Improvement After Partial Nephrectomy | GU Oncology Now
Dr. Afari elaborates on the factors he identified that contribute to renal function improvement post-partial nephrectomy.
New Noninvasive Urine Test Can Reduce Unnecessary Biopsies in Advanced Prostate Cancer | GU Oncology Now
A new 18-gene urine test developed by Dr. Jeffrey Tosoian and colleagues can improve PSA screening outcomes relative to existing biomarker tests in patients with…
The Uromigos Episode 310: Dosing and Duration of Drugs From a Cost Perspective | GU Oncology Now
Daniel Goldstein returns to the podcast to discuss dosing issues and dosing changes in drugs such as nivolumab and pembrolizumab, as well as other immune…
RNU Versus Kidney-Sparing Surgery for High-Grade UTUC | GU Oncology Now
Helen Gao highlights her comparative outcomes analysis of RNU and kidney-sparing surgery in the treatment of high-grade UTUC.
Daniel Spratt, MD – Offering Mentorship, Purpose for Aspiring Radiation Oncologists | GU Oncology Now
Dr. Spratt ponders the evolving integration of RT with systemic treatments, challenges in counseling patients, and more.
FDA Approves IL-15 Receptor Agonist for BCG-Unresponsive NMIBC | GU Oncology Now
The FDA approved Anktiva for patients with BCG-unresponsive NMIBC with CIS with or without papillary tumors.
Evaluating Gemcitabine, Docetaxel Versus Bacillus Calmette-Guérin in Patients With UTUC | GU Oncology Now
The only guideline-recommended endoluminal treatment option for patients with HG UTUC is bacillus Calmette-Guérin.
Molecular Testing for aUC: Navigating FGFR-Targeted Therapy | GU Oncology Now
Dr. Joshi contextualizes the THOR study within the treatment landscape for FGFR2/3-altered advanced urothelial carcinoma.
The Uromigos Episode 310: Dosing and Duration of Drugs From a Cost Perspective | GU Oncology Now
Daniel Goldstein returns to the podcast to discuss dosing issues and dosing changes in drugs such as nivolumab and pembrolizumab, as well as other immune…
Recent Updates in #Molecular Imaging for #ProstateCancer #Clinical Trials #cancer #news
Gary Ulaner, MD, PhD, FSNMMI, FACNM, of Hoag Family Cancer Institute, highlights 2 new clinical trials for prostate cancer staging and treatment: MIRROR and …